<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00007059</url>
  </required_header>
  <id_info>
    <org_study_id>NCRR-M01RR00046-1404</org_study_id>
    <secondary_id>UNCCH-GCRC-1404</secondary_id>
    <secondary_id>ROCHE-CEL028</secondary_id>
    <nct_id>NCT00007059</nct_id>
  </id_info>
  <brief_title>Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation</brief_title>
  <official_title>Study of the Pharmacokinetics of Mycophenolate Mofetil in Patients Who Have Undergone Orthotopic Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the effects of bile externalization and antibiotic gut sterilization&#xD;
      on the pharmacokinetics of mycophenolate mofetil in patients who have undergone orthotopic&#xD;
      liver transplantation.&#xD;
&#xD;
      II. Correlate serum concentrations of mycophenolic acid with inosine monophosphate&#xD;
      dehydrogenase activity in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      Patients begin a mycophenolate mofetil (MMF)-containing regimen within the first 5 days after&#xD;
      transplantation. Patients have blood drawn on postoperative days 7, 21, 42, 70, 98, 126, and&#xD;
      154. Urine is collected on postoperative days 7, 21, and 42. Patients with T-tube bile&#xD;
      externalization also have bile collected on postoperative day 7.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>20</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Orthotopic liver or kidney transplant recipients who started on a mycophenolate&#xD;
        mofetil-containing immunosuppressive regimen within 5 days after transplant&#xD;
&#xD;
        Kidney transplant recipients will serve as study controls&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
          -  No concurrent bile acid sequestrants&#xD;
&#xD;
          -  No mycophenolate mofetil as part of rescue therapy regimen&#xD;
&#xD;
          -  No concurrent albumin replacement therapy&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Renal: Urine output at least 500 mL/day OR Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  No mental incompetency&#xD;
&#xD;
          -  No prisoners or parolees HIV negative&#xD;
&#xD;
          -  No active infection defined as: Temperature above 101 F with WBC greater than&#xD;
             12,000/mm3 and left shift OR Two or more positive cultures of a single isolated&#xD;
             organism from blood, urine, or sputum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E. Dupuis</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>December 6, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>disease-related problem/condition</keyword>
  <keyword>graft versus host disease</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

